TrialThe Journal of dermatology2021

Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).

Atsuyuki Igarashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.